Nigel Russell, MD, from Nottingham University Hospitals NHS Trust, Nottingham, UK discusses how treatment for acute myeloid leukemia (AML) is becoming more personalized. Prof Rusell discusses mutational characteristics such as FLT3 and NPM1 and how different groups of patients benefit from different treatment approaches. For example, some patients appear to benefit from a high dose of anthracycline and some from the addition of Mylotarg therapy. Prof Russell talks about this in the context of the updated results of the AML17 trial, which showed that a sub-group of patients with the FLT3-ITD mutation appear to benefit from a higher dose of daunorubicin.
Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland.